HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference. This conference will be held virtually on March 26, 2024.
Dr. Vera will present an overview of Marker's advancements and clinical development programs on Tuesday, March 26, 2024, at 10 AM EDT.
Details of the presentation are as follows:
Event: | H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference |
Date: | March ... |